Aroa Biosurgery says Symphony DFU trial lifts 12-week complete closure rate to 55% vs 35% with standard care

• Aroa Biosurgery reported results from a randomized trial of Symphony for diabetic foot ulcers, published in the International Wound Journal.
• The study results have already been presented through publication, not flagged for a future conference release.
• Patients receiving Symphony with standard care saw better healing outcomes than standard care alone, with more wounds closing fully.
• Healing also occurred faster in the Symphony group, supporting a stronger clinical value proposition for reimbursement and adoption.
• The trial enrolled 143 patients across 10 U.S. sites, targeting harder-to-treat ulcers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aroa Biosurgery Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610050046PR_NEWS_USPR_____CN63279) on October 05, 2026, and is solely responsible for the information contained therein.